- Varies according to individual drug
- Most are self-administered subcutaneously, but some can be used IV or SC
- Rituximab and Belimumab are IV
- Infliximab IV or subcutaneous.
- JAK inhibitors (jakinibs) are oral
The aim of treatment is to suppress disease activity and preserve joint/organ function in the inflammatory arthropathies/SLE and vasculitides for those who have failed or are intolerant of methotrexate. Most are co-prescribed with methotrexate for increased efficacy.
At time of writing these are the Biologic/Small Molecule Targeted JAK inhibitor Drugs accepted for use in NHS Scotland:
Secretaries 01387 241776
Rheumatology Nurse Specialists Helpline 01387 241095 or dg.rheum-adviceline@nhs.scot
Department of Rheumatology doctors via Switchboard if urgent or RMS Advice request